A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC 710428) (IND 59699) Administered Every 21 Days in Patients With Hormone Refractory Prostate Cancer

Trial Profile

A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC 710428) (IND 59699) Administered Every 21 Days in Patients With Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2013

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 05 Nov 2010 New trial record.
    • 30 Jun 2004 Results presented at 40th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top